Hospital
Bowling Green-Warren County Community Hospital Corporation
Bowling Green-Warren County Community Hospital Corporation was paid $13.22M by Medicaid between Jan 2018 and Nov 2024, across 128 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoBOWLING GREEN-WARREN COUNTY COMMUNITY HOSPITAL CORPORATION
FRANKLIN, KY 42134
FRANKLIN, KY 42134
33aNPI1831173467assigned 12/06/2005
33bProvider typeCritical Access Hospital
28Total paid$13.22M
24GClaims216,352
24DCodes billed128
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#8 of 16
Median peer was paid$11.73M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWLESS, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,104 | $1.67M | |
| 2019 | 28,991 | $1.47M | |
| 2020 | 30,634 | $1.72M | |
| 2021 | 38,135 | $2.34M | |
| 2022 | 40,240 | $2.69M | |
| 2023 | 36,662 | $2.50M | |
| 2024incomplete | 12,586 | $829K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 10,707 | 8,624 | $2.88M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 5,940 | 4,227 | $2.08M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 14% | 1,735 | 1,390 | $1.80M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.3% | 7,566 | 6,580 | $1.23M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 1,956 | 1,521 | $630K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.8% | 1,108 | 929 | $509K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 4,187 | 3,349 | $308K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.3% | 4,473 | 3,921 | $307K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 8,280 | 4,258 | $303K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 4,191 | 3,291 | $216K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 24,212 | 12,767 | $211K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 4,093 | 3,401 | $205K |
116 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 2,619 | $178K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 4,345 | $165K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,490 | $129K |
| 80053 | Comprehensive metabolic panel | <1% | 12,593 | $129K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,598 | $120K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,205 | $106K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,678 | $100K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,577 | $96K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,306 | $94K |
| V2632 | Posterior chamber intraocular lens | <1% | 557 | $78K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,903 | $66K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,620 | $59K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,893 | $58K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 457 | $53K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 869 | $44K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,048 | $43K |
| 84484 | <1% | 4,005 | $41K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 343 | $41K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,107 | $38K |
| C1780 | Lens, intraocular (new technology) | <1% | 214 | $38K |
| 83880 | <1% | 1,282 | $34K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 483 | $33K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,586 | $33K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 141 | $31K |
| 80061 | Lipid panel | <1% | 2,067 | $30K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,433 | $29K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,195 | $28K |
| 73630 | <1% | 284 | $27K | |
| 83690 | <1% | 4,109 | $27K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,579 | $26K |
| 80306 | <1% | 1,849 | $26K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,931 | $25K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 319 | $24K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,019 | $24K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,603 | $21K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 269 | $19K |
| 87631 | <1% | 194 | $18K | |
| 84703 | <1% | 2,374 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,316 | $17K |
| 85379 | <1% | 1,793 | $15K | |
| J2704 | Injection, propofol, 10 mg | <1% | 792 | $15K |
| 81015 | <1% | 3,763 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 32 | $13K |
| 85730 | <1% | 2,318 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,748 | $12K |
| 94664 | <1% | 1,153 | $12K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,029 | $12K |
| 82150 | <1% | 1,917 | $12K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 394 | $12K |
| 93971 | <1% | 52 | $11K | |
| 84145 | <1% | 534 | $10K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 306 | $10K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 39 | $10K |
| 83605 | <1% | 1,051 | $10K | |
| 85610 | <1% | 2,918 | $9K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 84 | $9K |
| 81003 | <1% | 3,150 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $8K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 320 | $8K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 425 | $8K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 152 | $8K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 327 | $7K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 575 | $7K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 291 | $7K |
| 85027 | <1% | 750 | $6K | |
| 87040 | <1% | 589 | $6K | |
| 83735 | <1% | 1,136 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 35 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 396 | $5K |
| 82553 | <1% | 336 | $5K | |
| 82948 | <1% | 605 | $5K | |
| 80076 | <1% | 700 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 382 | $5K |
| 86140 | <1% | 1,133 | $5K | |
| 82550 | <1% | 610 | $4K | |
| 82607 | <1% | 324 | $4K | |
| 87634 | <1% | 93 | $4K | |
| 85651 | <1% | 1,121 | $3K | |
| 74018 | <1% | 33 | $3K | |
| J3490 | Unclassified drugs | <1% | 224 | $3K |
| 87486 | <1% | 121 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $3K |
| 87581 | <1% | 114 | $2K | |
| 87186 | <1% | 252 | $2K | |
| 36600 | <1% | 73 | $2K | |
| 90715 | <1% | 93 | $2K | |
| 84439 | <1% | 295 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 135 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 79 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 133 | $2K |
| 73562 | <1% | 19 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 200 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 138 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 89 | $1K |
| 81001 | <1% | 357 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 60 | $792.91 |
| 82803 | <1% | 56 | $782.10 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 12 | $672.98 |
| 82805 | <1% | 14 | $655.01 | |
| 87070 | <1% | 79 | $491.47 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 64 | $456.26 |
| 82375 | <1% | 55 | $441.26 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 20 | $440.45 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 32 | $354.27 |
| 82728 | <1% | 34 | $338.53 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 14 | $217.60 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $182.40 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $182.40 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 15 | $182.40 |
| 85018 | <1% | 84 | $150.45 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 22 | $143.68 |
| 87081 | <1% | 21 | $133.90 | |
| 86308 | <1% | 27 | $132.18 | |
| 82010 | <1% | 13 | $105.77 | |
| 86900 | <1% | 17 | $54.52 | |
| 86901 | <1% | 17 | $54.52 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWLESS, MICHELE (EXECUTIVE VICE PRESIDENT & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.